Regardless, this molecule did not affect HSP70 levels, in contrast to Bortezomib, a known proteasomal inhibitor currently used for the treatment of lymphoma/myeloma in the clinic [49], which shows a similar pattern to Foldlin, combining both p53 reduction and HSP70 induction (Figure 6B). Here, TP53 is linked to plasma cell myeloma.